Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: J Neurol Neurosurg Psychiatry. 2021 Apr 26;92(10):1062–1067. doi: 10.1136/jnnp-2021-326166

Table 2.

Cox regression models showing associations between anticoagulation status before the stroke and recurrent ischemic events and symptomatic intracranial hemorrhage

Recurrent ischemic event Symptomatic intracranial hemorrhage
Unadjusted 1.31 (0.89 – 1.94)
p = 0.171		 1.15 (0.50 – 2.66)
p = 0.744
Model 1 1.29 (0.87 – 1.90)
p = 0.208		 1.16 (0.50 – 2.68)
p = 0.731
Model 2 1.41 (0.94 – 2.11)
p = 0.102		 1.14 (0.50 – 2.65)
p = 0.748
Model 3 1.50 (0.99 – 2.28)
p = 0.058		 1.08 (0.46 – 2.51)
P = 0.862

Recurrent ischemic event: model 1 adjusted for CHADS2Vasc and model 2 adjusted for CHADS2Vasc, ipsilateral large artery disease with 50% or more luminal narrowing, and ischemic lesion < 10 mL, model 3 adjusted for model 2 plus anticoagulation initiated or continued (vs. not)

sICH: model 1 adjusted for age, sex, and ischemic lesion < 10 mL; model 2 adjusted for model 1 and bridging with LMWH/heparin; model 3 adjusted for model 2 plus anticoagulation initiated; LMWH, low-molecular-weight heparin; sICH, symptomatic intracranial haemorrhage.